Status:
RECRUITING
A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Lead Sponsor:
Eli Lilly and Company
Conditions:
Juvenile Idiopathic Arthritis
Eligibility:
All Genders
1-18 years
Phase:
PHASE3
Brief Summary
The reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in ...
Eligibility Criteria
Inclusion
- Participants must have completed a previous study of baricitinib for the treatment of JIA.
Exclusion
- Participants must not have had a permanent discontinuation of baricitinib in the prior study.
- Participants must have not developed an allergy to baricitinib.
Key Trial Info
Start Date :
April 5 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2031
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT03773965
Start Date
April 5 2019
End Date
July 1 2031
Last Update
December 8 2025
Active Locations (83)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto CAICI SRL
Rosario, Argentina, S2000
2
Centro de Investigaciones Médicas Tucuman
SAN M. de Tucuman, Argentina, T4000AXL
3
Royal Children's Hospital
Melbourne, Australia, 3052
4
Perth Children's Hospital
Perth, Australia, 6009